Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients

Anthracyclines remain a cornerstone of cancer therapy but are associated with a significant risk of cardiotoxicity, which can lead to overt heart failure. The risk is modulated by cumulative dose, pre-existing cardiovascular disease, and patient-specific factors. As cancer survival improves, the lon...

Full description

Saved in:

Bibliographic Details
Main Authors:	Luigi Spadafora, Francesca Maria Di Muro, Chiara Intonti, Ludovica Massa, Mauro Monelli, Roberto Franco Enrico Pedretti, Edvige Palazzo Adriano, Pasquale Guarini, Gaia Cantiello, Marco Bernardi, Federico Russo, Stefano Cacciatore, Pierre Sabouret, Michele Golino, Giuseppe Biondi Zoccai, Francesca Romana Zimatore, Laura Adelaide Dalla Vecchia
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Journal of Cardiovascular Development and Disease
Subjects:	anthracyclines anthracycline-induced cardiotoxicity prevention exercise pharmacological strategies cardio-oncology
Online Access:	https://www.mdpi.com/2308-3425/12/6/212
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity
by: Rongrong Bai, et al.
Published: (2025-06-01)

Racial and Ethnic Disparities in Cardiotoxicity in Patients With Cancer Treated With Anthracyclines
by: Lili Zhang, et al.
Published: (2025-04-01)

Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity
by: John Lee, et al.
Published: (2024-12-01)

MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances
by: Hongyun Mao, et al.
Published: (2025-08-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

Roles of Non-Coding RNA in Anthracycline Cardiotoxicity: A Narrative Review
by: Xiao S, et al.
Published: (2025-07-01)

Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity
by: I. T. Murkamilov, et al.
Published: (2021-03-01)

Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis
by: Ling Yin Fritz Wong, et al.
Published: (2025-07-01)

Functional investigation of the SAM-dependent methyltransferase RdmB in anthracycline biosynthesis
by: Moli Sang, et al.
Published: (2025-03-01)

Anthracycline-induced cardiac toxicity: A clinical review
by: Adil Abdelhameed Abbas, et al.
Published: (2019-01-01)

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
by: V. I. Chernov, et al.
Published: (2016-02-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis
by: Runyu Liu, et al.
Published: (2025-07-01)

POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
by: Yu. V. Vasyuk, et al.
Published: (2017-05-01)

Prevention and treatment of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis of randomized controlled trials
by: Siyu Li, et al.
Published: (2025-07-01)

Creation of anthracycline prodrug
by: A. N. Tevyashova
Published: (2014-12-01)

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases
by: E. V. Grakova, et al.
Published: (2023-01-01)

Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer—a retrospective cohort study
by: Árpád Kézdi, et al.
Published: (2025-04-01)

Prognostic value of humoral markers in patients with anthracycline-related cardiac dysfunction
by: E. V. Grakova, et al.
Published: (2023-10-01)

Randomized, Placebo‐Controlled, Triple‐Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline‐Based Cancer Therapy
by: Stephanie Itala Rizk, et al.
Published: (2025-05-01)

Combined Utility of Speckle Tracking Echocardiography and Cardiac Biomarkers for Early Detection of Anthracycline-Induced Cardiotoxicity in Pediatric Oncology Patients
by: Cristiana Stolojanu, et al.
Published: (2024-12-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)

Course of arterial hypertension during breast cancer chemotherapy with anthracyclines
by: E. N. Berezikova, et al.
Published: (2024-10-01)

Ischemic stroke as the first manifestation of anthracycline cardiomyopathy
by: G. R. Ramazanov, et al.
Published: (2023-01-01)

RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS
by: N. T. Vatutin, et al.
Published: (2017-10-01)

Nuclear imaging of chemotherapy-induced cardiotoxicity
by: A. A. Ansheles, et al.
Published: (2021-03-01)

Evaluation of left atrial strain changes in patients with breast cancer after anthracycline therapy
by: Mostafa El Mokadem, et al.
Published: (2025-05-01)

Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database
by: Danyi Liu, et al.
Published: (2024-12-01)

The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
by: D. A. Andreev, et al.
Published: (2024-03-01)

Ejection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center
by: Rizkyastari Onny, et al.
Published: (2025-06-01)

RADIONUCLIDE METHODS IN THE DETECTION AND FORECAST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN BREAST CANCER PATIENTS
by: V. I. Chernov, et al.
Published: (2016-12-01)

Clinical, Echocardiographic and Laboratory Cardiac Monitoring in Breast Cancer Patients Undergoing Chemotherapy with Anthracycline Agents: A Pilot Study on Cardioprotective Algorithms at Mohammad Hoesin General Hospital, Palembang
by: Indah Puspita
Published: (2025-07-01)

Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
by: L. M. Kogoniya, et al.
Published: (2022-07-01)

Treatment of cardiotoxicity in patients with invasive breast cancer during neoadjuvant chemotherapy
by: Grigorii A. Ignatenko, et al.
Published: (2024-09-01)

Efficacy and harms associated with β-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
by: Jessica T. Li, et al.
Published: (2024-06-01)

Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update
by: Vasvi Bhutani, et al.
Published: (2025-05-01)

Pregnancy associated cardiomyopathy in 2 cancer survivors with history of anthracycline use
by: Ramy Zughul, et al.
Published: (2025-06-01)

Utility of global longitudinal strain in early identification of chronic cardiotoxicity in asymptomatic long-term malignant lymphoma survivors with normal left ventricle ejection fraction
by: Eva Rihackova, et al.
Published: (2025-03-01)

Alternative mRNA splicing in anthracycline-induced cardiomyopathy – a COG-ALTE03N1 report
by: Purnima Singh, et al.
Published: (2025-05-01)